Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) CFO Erick Lucera sold 1,991 shares of Dyne Therapeutics stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $16.82, for a total value of $33,488.62. Following the transaction, the chief financial officer directly owned 117,775 shares in the company, valued at approximately $1,980,975.50. The trade was a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Dyne Therapeutics Stock Performance
Dyne Therapeutics stock traded down $0.46 during midday trading on Monday, hitting $16.70. The stock had a trading volume of 1,849,634 shares, compared to its average volume of 2,331,563. The firm’s fifty day moving average is $16.96 and its two-hundred day moving average is $19.33. The company has a market capitalization of $3.13 billion, a PE ratio of -4.60 and a beta of 1.22. Dyne Therapeutics, Inc. has a 52-week low of $14.00 and a 52-week high of $27.31. The company has a current ratio of 12.99, a quick ratio of 12.99 and a debt-to-equity ratio of 0.21.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same quarter last year, the firm earned ($0.76) EPS. On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.81 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on DYN shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Stifel Nicolaus set a $37.00 price target on Dyne Therapeutics in a report on Wednesday, September 30th. Wall Street Zen downgraded Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 29th. Finally, HC Wainwright cut their target price on Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.29.
Check Out Our Latest Stock Report on Dyne Therapeutics
Institutional Trading of Dyne Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of DYN. The Manufacturers Life Insurance Company bought a new position in shares of Dyne Therapeutics during the 2nd quarter valued at approximately $1,746,000. Handelsbanken Fonder AB purchased a new position in shares of Dyne Therapeutics in the second quarter valued at $1,182,000. Palo Alto Investors LP bought a new stake in Dyne Therapeutics in the second quarter worth $36,591,441. Flputnam Investment Management Co. bought a new stake in Dyne Therapeutics in the second quarter worth $1,177,000. Finally, Royal Bank of Canada increased its position in Dyne Therapeutics by 267.6% in the first quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock worth $1,236,000 after purchasing an additional 49,641 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.
Dyne Therapeutics Company Profile
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.
Further Reading
- Five stocks we like better than Dyne Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
